Predictors of high-flow nasal cannula (HFNC) failure in severe community-acquired pneumonia or COVID-19
- PMID: 39733203
- DOI: 10.1007/s11739-024-03844-9
Predictors of high-flow nasal cannula (HFNC) failure in severe community-acquired pneumonia or COVID-19
Abstract
The aim was to identify predictors for early identification of HFNC failure risk in patients with severe community-acquired (CAP) pneumonia or COVID-19. Data from adult critically ill patients admitted with CAP or COVID-19 and the need for ventilatory support were retrospectively analysed. HFNC failure was defined as the need for invasive ventilation or death before intubation. 60 patients with CAP and 185 with COVID-19 were included. 27 (45%) patients with CAP and 69 (37.3%) patients with COVID-19 showed HFNC failure. Lower oxygenation index, lower respiratory oxygenation (ROX) index, and higher respiratory rate at the start of HFNC were significantly associated with HFNC failure. ROC-analysis identified a respiratory rate of 27/min as the optimal cut-off for predicting HFNC failure, with a specificity of 59% and a sensitivity of 75%, and an oxygenation index after HFNC initiation of 99.6 (specificity 81%, sensitivity 74%). In COVID-19, an elevated CRB65-score at hospital admission and at HFNC-initiation was significantly associated with HFNC failure. In CAP and COVID patients an oxygenation index < 99.6, a respiratory rate > 27/min and a ROX index < 4.88 were predictors for HFNC failure whereas a CRB65 score > 3 at hospital admission and > 2 at HFNC start was predictive for HFNC failure in COVID-19.
Keywords: High-flow nasal cannula; NIV failure; Pneumonia; Respiratory failure.
© 2024. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Conflict of interest statement
Declarations. Conflict of interest: A. Grünewaldt reports personal fees from Boehringer Ingelheim for lectures and GSK for consultancy during advisory board meetings. G. Rohde reports personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for consultancy during advisory board meetings, furthermore personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures. M. Gaillard reports no competing interests. Ethical approval: The study protocol was endorsed by the local ethics committee of the university hospital, Goethe university Frankfurt (study number 22-785).
Similar articles
-
Respiratory-rate Oxygenation index for Predicting Noninvasive Ventilation Associated With High-flow Nasal Cannula Failure in Acute Respiratory Failure Due to SARS-CoV-2.J Intensive Care Med. 2025 Feb;40(2):151-163. doi: 10.1177/08850666241268452. Epub 2024 Dec 9. J Intensive Care Med. 2025. PMID: 39654395
-
Reliability of the respiratory rate and oxygenation index for successful high-flow nasal cannula support in coronavirus disease pneumonia: a retrospective cohort study.BMC Pulm Med. 2023 Aug 10;23(1):294. doi: 10.1186/s12890-023-02598-y. BMC Pulm Med. 2023. PMID: 37559018 Free PMC article.
-
Use of high-flow nasal cannula oxygen and risk factors for high-flow nasal cannula oxygen failure in critically-ill patients with COVID-19.Respir Res. 2022 Dec 3;23(1):329. doi: 10.1186/s12931-022-02231-2. Respir Res. 2022. PMID: 36463161 Free PMC article.
-
Performance of the ROX index in predicting high flow nasal cannula failure in COVID-19 patients: a systematic review and meta-analysis.Crit Care. 2023 Aug 21;27(1):320. doi: 10.1186/s13054-023-04567-7. Crit Care. 2023. PMID: 37605238 Free PMC article.
-
The ROX index as a predictor of high-flow nasal cannula outcome in pneumonia patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis.BMC Pulm Med. 2022 Apr 1;22(1):121. doi: 10.1186/s12890-022-01914-2. BMC Pulm Med. 2022. PMID: 35365110 Free PMC article.
Cited by
-
Predictors of high‑flow nasal cannula (HFNC) failure in severe community‑acquired pneumonia or COVID‑19: comment.Intern Emerg Med. 2025 Aug;20(5):1643-1644. doi: 10.1007/s11739-025-03917-3. Epub 2025 Mar 12. Intern Emerg Med. 2025. PMID: 40072678 No abstract available.
References
LinkOut - more resources
Full Text Sources
Miscellaneous